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Erythropoietin (EPO) primarily activates erythroid cell proliferation and growth and is active
in several types of non-hematopoietic cells via its interaction with the EPO-receptor
(EPO-R). This review focuses on the role of EPO in skeletal muscle. The EPO-R is
expressed in skeletal muscle cells and EPO may promote myoblast differentiation and
survival via the activation of the same signaling cascades as in hematopoietic cells, such
as STAT5, MAPK and Akt. Inconsistent results exist with respect to the detection of
the EPO-R mRNA and protein in muscle cells, tissue and across species and the use
of non-specific EPO-R antibodies contributes to this problem. Additionally, the inability
to reproducibly detect an activation of the known EPO-induced signaling pathways in
skeletal muscle questions the functionality of the EPO-R in muscle in vivo. These equivocal
findings make it difficult to distinguish between a direct effect of EPO on skeletal muscle,
via the activation of its receptor, and an indirect effect resulting from a better oxygen supply
to the muscle. Consequently, the precise role of EPO in skeletal muscle and its regulatory
mechanism/s remain to be elucidated. Further studies are required to comprehensively
establish the importance of EPO and its function in skeletal muscle health.
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EPO, A PLEIOTROPIC HORMONE
Erythropoietin (EPO) is a cytokine hormone primarily dedicated
to erythroid progenitor cell development and proliferation. After
birth, EPO is essentially synthetized in the peritubular fibroblast-
like cells located in the cortex of the kidneys (Maxwell et al., 1993,
1997). Its production is largely stimulated by tissue hypoxia and
results in an increased number of circulating erythrocytes and,
consequently, in an improved oxygen supply to the active tis-
sues (Jelkmann, 2004; Noguchi et al., 2008; Jelkmann, 2011). In
the last decade, numerous studies reported that apart from its
hematopoietic effect, EPOwas active locally inmany other tissues,
including endothelial, neural, muscle, cardiovascular and renal
tissues, in response to physical or metabolic stress. Accordingly,
the expression of the specific EPO receptor (EPO-R) extends
beyond hematopoietic cells [previously reviewed in Noguchi et al.
(2008)]. Based on these findings, pleiotropic functions have been
proposed for EPO, which has notably been suggested to be
involved in protection against oxidative stress in neuronal cells
(Zaman et al., 1999), in neovascularization in uterine angio-
genesis (Yasuda et al., 1998) and in maintenance and repair of
myocardium (Tada et al., 2006). This review focuses on the role of
EPO and its specific receptor (EPO-R) in skeletal muscle tissue.
STRUCTURE AND FUNCTION OF EPO AND ITS RECEPTOR
The circulating human EPO protein is made of 166 amino acids
(Miyake et al., 1977; Jacobs et al., 1985; Lin et al., 1985). Two
antiparallel pairs of α-helical bundles linked by two disulphide
bridges between Cys residues (Jacobs et al., 1985; Lin et al., 1985)
form a glomerular structure analogous to the structure of growth
hormone despite little similarity in amino acid sequence (Wen
et al., 1994). EPO is a highly glycosylated protein. The molec-
ular mass of the peptide backbone of EPO is 18 kDa, whereas
the molecular mass of the glycoprotein is 30.4 kDa. Human EPO
includes three N-linked (Asn24, Asn38, Asn83) and one O-linked
(Ser126) acidic oligosaccharide side chains (Dordal et al., 1985;
Sasaki et al., 1987). Structural modifications or permutations of
the carbohydrate chains can alter the molecular mass, biological
activity, electric charge or immunoreactivity of the EPO protein
(Wide and Bengtsson, 1990; Wasley et al., 1991; Hammerling
et al., 1996; Jelkmann, 2007).
EPO primarily exerts its effect by binding a cytokine class
I receptor superfamily member, the EPO-receptor (EPO-R)
(D’Andrea and Zon, 1990; Youssoufian et al., 1993). The EPO-
R is a 508 amino acids transmembrane receptor (Noguchi et al.,
1991) including an extracellular domain containing a WSXWS
motif, a single transmembrane hydrophobic domain and a vari-
able cytoplasmic domain (Youssoufian et al., 1993). The active
form of the EPO-R on the surface of erythroid progenitor cells
is a homodimer. Different models of hematopoietic and non-
hematopoietic cell lines have allowed to establish that EPO bind-
ing induces a conformational change in two adjacent monomeric
EPO-R molecules, which leads to the phosphorylation of the
cytoplasmic domain-associated JAK2 proteins (Constantinescu
et al., 1999; Remy et al., 1999), their activation of a JAK2 Tyr
kinase (Witthuhn et al., 1993) and the consequent phosphory-
lation of the EPO-R (Miura et al., 1991; Dusanter-Fourt et al.,
1992). EPO-induced JAK2 activation provokes STAT5 phospho-
rylation and translocation to the nucleus where it activates the
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transcription of its target genes (Damen et al., 1995; Pallard
et al., 1995; Penta and Sawyer, 1995; Klingmuller et al., 1996;
Quelle et al., 1996). In addition, JAK2 activation has the potential
to trigger various signaling cascades in response to EPO bind-
ing. The Ras/mitogen-activated kinase (MAPK) pathway and the
phosphatidylinositol 3-kinase (PI3)/Akt pathway are notably acti-
vated by EPO in interleukin-3-dependent cell lines expressing
high levels of EPO-R (Damen et al., 1993; Miura et al., 1994;
Constantinescu et al., 1999; Fisher, 2003).
Alternatively, it was previously reported that the EPO-R could
physically associate and interact with the common β receptor
(βcR) subunit (Jubinsky et al., 1997; Blake et al., 2002), suggesting
a potential role of βcR in EPO signaling. However, βcR knock-
out mice exhibit normal hematopoiesis (Scott et al., 2000). It
was therefore proposed that a heteroreceptor complex compris-
ing both EPO-R and βcR could, at least partially, mediate the
non-hematopoietic functions of EPO (Brines et al., 2004).
EXPRESSION OF THE EPO-R AND ITS ROLE IN
INTRACELLULAR SIGNALING
Ogilvie and colleagues first reported that the EPO-R gene and
protein were expressed in primary satellite cells isolated from
mouse skeletal muscle and in cultured C2C12 myoblasts. EPO-R
gene expression was downregulated during the differentiation
of C2C12 myoblasts to myotubes (Ogilvie et al., 2000), a phe-
nomenon analogous to that observed during erythropoiesis
where EPO-R is not expressed inmature red blood cells. However,
EPO-R gene expression increased with myoblast proliferation (Jia
et al., 2009), suggesting a role in regeneration. Mouse embryos
expressing the lacZ reporter gene, driven by the human EPO-
R promoter, showed in-situ hybridization staining in the region
of the visceral arches and base of limbs, suggesting a role for
EPO-R in the developing muscle (Ogilvie et al., 2000). However,
EPO-R mRNA expression was not detected in the skeletal mus-
cle of adult transgenic mice expressing the human EPO-R gene
(Liu et al., 1994, 1997), although it was not detected in any other
non-hematopoietic tissue either. Presence of the rat and human
EPO-R mRNA and protein was reported in rat L6 myoblasts
and in human primary myoblast cultures, respectively (Launay
et al., 2010). In contrast, EPO-R gene and protein expression
was not detected in rat myoblasts isolated from normal mus-
cle, while a transient, unexplained induction was observed 1 and
7 days following a mechanical-induced muscle injury (Rotter
et al., 2008). The EPO-R protein was detected in cross sections
of human skeletal muscle tissue and was primarily localized in
the region of vascular cells and of the skeletal muscle membrane
(sarcolemma) (Lundby et al., 2008a; Rundqvist et al., 2009). The
presence of EPO-R mRNA and protein in skeletal muscle biopsies
has been reported while EPO-R mRNA has been detected in iso-
lated human muscle fibers and human satellite cells. Finally, the
EPO-R protein was detected in total muscle extracts from muscle
biopsies (Rundqvist et al., 2009; Christensen et al., 2012a). These
results strongly suggest that the EPO-R mRNA is present in mus-
cle tissue, although differences may exist between species and cell
lines.
It was suggested that expression of the EPO-R gene was trig-
gered by EPO stimulation. C2C12 cells cultured in the presence
of EPO showed a substantial increase in EPO-R gene expression
(Ogilvie et al., 2000) and an increase in EPO-R protein levels in
both normoxic and hypoxic conditions (Jia et al., 2009). EPO
transgenic mice with chronically elevated circulating levels of
EPO displayed higher EPO-R mRNA levels in primary myoblasts
when compared with wild-type mice. Inversely, knockdown of
circulating EPO levels did not lead to any change in EPO-R gene
expression in transgenic mouse muscle (Hagstrom et al., 2010a;
Mille-Hamard et al., 2012). Similarly in human muscle, EPO-R
gene expression was not modified by acute EPO administration
(Lundby et al., 2008a).
Discrepancies in the measurement of EPO-R mRNA and pro-
tein levels appear to be related to potential species differences and
the use of in vitro verses in vivo models. Studies using human
primary muscle cells and mouse muscle in vivo will help to
clarify some of these inconsistencies. Furthermore, concerns sur-
rounding antibody specificity (Elliott et al., 2006; Kirkeby et al.,
2007) (discussed in detail below) suggest that conclusions drawn
about EPO-R protein expression, role and functionality in skeletal
muscle need to be considered with caution.
Whether the EPO-R has the potential to activate the same sig-
naling cascades in skeletal muscle (Figure 1) as in hematopoietic
cells remains unclear. C2C12 myoblasts treated with EPO dis-
played an increase in JAK2, STAT5 (Ogilvie et al., 2000) and Akt
phosphorylation (Jia et al., 2012); similar to signaling responses
observed in neural cells. Furthermore, supraphysiological EPO
concentrations activated Akt in mouse muscle (Hojman et al.,
2009). However, STAT5 activation was not detected in rat skeletal
muscle tissue following EPO stimulation (Lebaron et al., 2007).
Acute EPO administration did not lead to any change in the phos-
phorylation levels of members of the STAT5, Akt and MAPK
signaling pathways in human skeletal muscle (Christensen et al.,
2012a). It is of interest to note that no EPO-induced response
could be observed in endothelial and other non-hematopoietic
cells, which had previously been described to be EPO-responsive
(Sinclair et al., 2010). However, it must be noted that activation
of Akt phosphorylation was also observed in the vehicle treated
group, making it impossible to establish the specific effect of EPO
on Akt signaling.
CONTROVERSY SURROUNDING EPO-R ANTIBODIES
Discrepancies between results obtained for EPO-R gene and pro-
tein expression or across species may be attributable to the non-
specificity of certain commercially available EPO-R antibodies
(Table 1).
A study comparing 4 commercially available antibod-
ies showed that only the M-20 clone (sc-697, Santa Cruz
Biotechnology) was suitable for detection of the EPO-R pro-
tein by Western Blot and that none, including the M-20 clone,
was suitable for immunohistochemistry. The predicted molecu-
lar weight of the mature, membrane-bound form of the EPO-R
protein is 56–57 kDa (Kuramochi et al., 1990; Nakamura et al.,
1992; Fujita et al., 1997). While each antibody detected more than
one band between 50–75 kDa, sequence analyses confirmed the
EPO-R sequence in the 59 kDa band recognized by theM-20 anti-
body only (Elliott et al., 2006). Out of 6 commercially available
antibodies, 5 of these antibodies detected rat or human EPO-R
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FIGURE 1 | Signaling cascades activated by EPO in skeletal muscle., activated by EPO; ✘, not activated by EPO; ?, not investigated.
when overexpressed in HEK293 cells, but only 2 of these detected
endogenous EPO-R in the human hematopoietic UT-7 cell line.
Rodent brain is known to express high levels of the EPO-R (Yu
et al., 2002); however, none of these antibodies was able to detect
the EPO-R protein in rat brain homogenates. No certainty could
be drawn either regarding the use of these various antibodies
in immunohistochemistry (Kirkeby et al., 2007). These conflict-
ing results illustrate the issues associated with various EPO-R
antibodies. The EPO-R protein has been shown to be highly
expressed in endothelial cells and other non-hematopoietic cells
(Tramontano et al., 2003; Arcasoy, 2008; Noguchi et al., 2008).
However, Sinclair et al. questioned the detectability of a functional
EPO-R protein in non-hematopoietic cells. Using a previously
validated, custom-made EPO-R antibody (Elliott et al., 2010),
they demonstrated that the expression of the EPO-R protein was
absent or 300- to 1000-fold lower in different types of endothe-
lial cells when compared to hematopoietic UT-7 cells (Sinclair
et al., 2010). However, UT-7 cells are engineered to translate 7 to
8 copies of the EPO-R gene (Chretien et al., 1994), resulting in a
high expression level of the EPO-R protein (Kirkeby et al., 2007).
Therefore, comparisons with physiological expression levels must
be interpreted cautiously.
This controversy is well exemplified in human skeletal muscle.
While the anti-EPO-R antibody used for immunohistochem-
istry by Rundqvist et al. was not precisely described (Rundqvist
et al., 2009), the specificity of the antibody used by Lundby
et al. (MAB307, R&D Systems) (Lundby et al., 2008a) has been
questioned (Kirkeby et al., 2007). Indeed, the MAB307 clone
exhibited a diffuse, non-specific staining in the cytoplasm, as well
as some degree of nuclear staining in rat brain tissue, indicating
non-specific binding. In muscle homogenates, Christensen et al.
identified a band corresponding to the 59 kDa EPO-R seen in
the positive control sample (K562 cell extracts) with the M-20
clone (Santa Cruz biotechnology), but not with the C-20 clone
(Santa Cruz biotechnology), while Rundqvist et al. used the C-
20 clone with the same positive control (K562 cell extracts) to
assess the presence of the EPO-R in muscle (Rundqvist et al.,
2009; Christensen et al., 2012a).
There are considerable concerns about the lack of speci-
ficity of numerous commercially available EPO-R antibodies.
A more rigorous approach to measuring EPO-R protein lev-
els in whole muscle homogenates and muscle cross-sections is
therefore required. This should include the demonstration of
appropriately validated EPO-R antibodies that detect not only an
overexpressed exogenous EPO-R protein, but also detect in paral-
lel the endogenous skeletal muscle EPO-R protein. The inclusion
of negative control samples from muscle tissues or muscle cells
that have an ablation of the EPO-R protein would be desirable.
These positive and negative controls should be species specific
for human and murine EPO-R proteins and include informa-
tion relating to protein sequencing of the detected EPO-R protein
bands.
EFFECTS OF EPO IN SKELETAL MUSCLE
IN VITRO
In line with its role in erythroid progenitor cells, EPO has been
proposed to promote proliferation and survival in myoblasts
(Figure 2). EPO stimulation enhanced proliferation and reduced
differentiation and fusion of both satellite and C2C12 cells
(Ogilvie et al., 2000; Jia et al., 2009). These effects were associ-
ated with an increase in the early myogenic regulatory factors
(MRFs) Myf-5 and MyoD gene expression and a delay or inhi-
bition in myogenin gene expression (Ogilvie et al., 2000). It
was recently demonstrated that EPO exerted its positive effects
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Table 1 | Detectability of the EPO-R in skeletal muscle.
Study Specie Tissue EPO-R gene
expression (method)
EPO-R protein
expression (method)
EPO-R antibody
Ogilvie et al., 2000 Mouse C2C12 myoblasts Yes (northern blot) Yes (WB)
Rabbit polyclonal antibodyYes (immunohistochemistry)
(Santa Cruz
Primary satellite cells Yes (RT-PCR) Yes (WB)
Biotechnology)
Yes (immunohistochemistry)
Embryos developing
muscle
Yes (in situ-
hybridization)
N/A
Jia et al., 2009 Mouse Primary myoblasts N/A Yes (immunohistochemistry) M-20 clone (Santa Cruz
Biotechnology)
Wang et al., 2012 Mouse C2C12 myoblasts Yes (RT-PCR) Yes (WB) EPO-R antibody (Santa
Cruz Biotechnology)
Liu et al., 1994, 1997 Mouse Muscle No (RT-PCR) N/A N/A
Launay et al., 2010 Rat L6 myoblasts Yes (RT-PCR) Yes (WB)
M-20 clone (Santa Cruz
Human Primary myoblasts Yes (RT-PCR) Yes (WB)
Biotechnology)
Rotter et al., 2008 Rat Primary myoblasts Transient (RT-PCR) Transient
(immunohistochemistry,
data not shown)
unknown
Lundby et al., 2008a Human Muscle Yes (RT-PCR) Yes (immunohistochemistry) MAB307 (R&D Systems)
Rundqvist et al., 2009 Human Muscle Yes (RT-PCR) Yes (immunohistochemistry) murine anti-human EPOR
antibody (R&D Systems)
Yes (WB) C-20 clone (Santa Cruz
Biotechnology) and
MAB287 (R&D Systems)
Isolated muscle
fibers
Yes (RT-PCR) N/A
Primary satellite cells Yes (RT-PCR) N/A
Christensen et al.,
2012a
Human Muscle N/A Yes (WB) M-20 clone (Santa Cruz
Biotechnology)
on myoblast proliferation and regulated MRFs via its induc-
tion of sirtuin1 (Sirt1), GATA-4 and T-cell acute leukemia 1
(TAL1) (Wang et al., 2012). Similarly, MRFs displayed an expres-
sion pattern characteristic of the early differentiation stages in
C2C12 cells overexpressing the EPO-R cultured in differentia-
tion media (Jia et al., 2009). The same study showed that EPO
treatment protected myoblasts against hypoxia-induced apop-
tosis. It was also proposed that EPO supplementation alone
(Rotter et al., 2008) or coupled with enhanced EPO-R expres-
sion (Jia et al., 2009) promoted rat and mouse myoblast survival,
respectively, under serum-starved conditions. Mouse myoblasts
extracted from muscle lacking the EPO-R did not prolifer-
ate in culture, while a higher proliferation and survival rate
was observed in myoblasts extracted from transgenic mice with
chronically elevated circulating EPO (Jia et al., 2012). In contrast
to these results, EPO treatment did not promote proliferation
or postpone differentiation in rat or human myoblasts cultured
in either normoxic or hypoxic conditions (Launay et al., 2010).
Furthermore, EPO supplementation did not decrease apopto-
sis in rat myoblasts (Rotter et al., 2008). While several types
of recombinant EPO molecules have been used in these stud-
ies (epoetin-alpha and/or -beta), the doses used for in vitro
treatments were reasonably consistent between studies (generally
0.5–10 IU/mL), except for the study by Rotter et al. who used
50 IU/mL.
IN RODENTMODELS
Expression of the EPO-R in non-hematopoietic cell lineages is
not necessary for normal mouse development. Transgenic mice
expressing the EPO-R exclusively in the hematopoietic lineage
displayed normal development, fertility and survival (Suzuki
et al., 2002). However, the lack of EPO-R in non-hematopoietic
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FIGURE 2 | Effects of EPO in skeletal muscle., activated by EPO. ✘,
not activated by EPO. ?, contradictory results. In vitro, EPO treatment
increases mouse, but not rat or human myoblast proliferation. EPO
treatment decreases differentiation and fusion of mouse, but not rat or
human myoblasts. EPO treatment protects against apoptosis in mouse
but not in rat myoblasts. In rodents, EPO treatment increases muscle
regeneration and angiogenesis following injury. In humans, EPO
treatment increases skeletal muscle hypertrophy and angiogenesis in
diseased conditions (chronic renal failure and Friedreich ataxia,
respectively), but has no effect in healthy muscle. In both rodent and
human studies, EPO has been shown to increase or have no effect on
muscle oxidative capacity. Note that it is presently unknown if the
effects of EPO treatment observed in rodent and human skeletal
muscle are direct or indirect.
tissues seems to compromise muscle regeneration and repair fol-
lowing injury. In a model of cardiotoxin-induced muscle injury,
mice with EPO-R expression restricted to hematopoietic tissues
had a reduced number of satellite cells and were more sensitive to
muscle injury than wild-type controls (Jia et al., 2012).
It has been suggested that EPO exposure could improve muscle
function in trauma or disease conditions. Local EPO treatment
increases rat soleus muscle regeneration and strength follow-
ing mechanically induced injury (Figure 2); a response associ-
ated with increased proliferating satellite cells numbers (Rotter
et al., 2008). Systemic EPO treatment has a similar effect fol-
lowing a combined muscle-nerve injury. Histological analysis of
muscle tissue demonstrated increased proliferation of satellite
cells and reduced cell apoptosis (Rotter et al., 2012). Mice with
chronically elevated circulating EPO displayed reduced injury
and accelerated recovery (Jia et al., 2012). In a model of severe
mouse sepsis, EPO treatment rapidly increased capillary density
and led to a normalization of skeletal muscle microcirculation
and tissue metabolism (Kao et al., 2007). Interestingly, C2C12
myoblasts overexpressing the EPO-R transplanted into muscle
fibers were able to restore dystrophin protein expression in mdx
mice, a mouse model for Duchenne muscular dystrophy (Jia
et al., 2009). Furthermore, this effect was enhanced by EPO
administration.
Several groups used EPO deficient mouse models to investi-
gate the potential of a direct or indirect role of EPO in skeletal
muscle development and function. No difference in muscle fiber
distribution, fatigability or tetanic force was reported for EDL
and soleus muscle of EPO deficient mice, either in normoxic
or in hypoxic conditions, when compared to wild-type controls
(Hagstrom et al., 2010b). EPO deficiency did not result in muscle
fiber atrophy or microvessel network alteration, two markers of a
poor EPO function in human (Hagstrom et al., 2010a). However,
microarray analysis in skeletal muscle from EPO-deficient mice
identified increases in genes related to muscle hypoxia, proteoly-
sis, cell death and apoptosis as well as reductions in genes involved
in glycolysis and mitochondrial function. These findings sup-
port the hypothesis that EPO has a protective effect in muscle
(Mille-Hamard et al., 2012). Although there is conflicting evi-
dence, some data support the role of EPO in a protection against
disease or trauma. However, its presence may not be required for
the maintenance of normal adult muscle function.
Several studies recently suggested that EPO treatment might
affect the oxidative properties of skeletal muscle and induce a
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shift towards a more oxidative phenotype. In both sedentary and
exercising rats, 2 weeks of EPO treatment increased the activ-
ity of several oxidative enzymes in different muscles, including
cytochrome C oxidase in the soleus muscle but not in the vastus
lateralis or in the gastrocnemius muscles. A general increase in
the expression of slow twitch myosin light chains and oxidative
myosin heavy chains following EPO treatment was also reported
following endurance training. Combining training with EPO had
additive effects (Cayla et al., 2008). In contrast to these results, rats
receiving EPO displayed significant decreases in the expression of
proteins involved in the mitochondrial biogenesis pathway, such
as PGC-1α, mTFA and cytochrome c, in the gastrocnemius but
not in the soleus muscle (Martinez-Bello et al., 2012). EPO was
also suggested to prevent the impairment of mitochondrial struc-
ture and function induced by a local anaesthetic in rat muscle
(Nouette-Gaulain et al., 2009). Alternatively to EPO adminis-
tration, EPO gene electrotransfer results in supraphysiological
circulating levels of EPO in muscle. In this model, when placed
on a high fat diet, mice gained less body fat and presented mus-
cle hypertrophy as well as increases in oxidative myosin heavy
chain I mRNA expression, vascularization, lipid oxidation and
expression of genes involved in fat metabolism and thermogenesis
(Hojman et al., 2009). However, these mice displayed a 100-fold
higher serum EPO concentration when compared to WT; there-
fore, the physiological relevance of such results is questionable.
On the other hand, it has previously been shown that hyperoxia
could augment muscle oxidative capacity (Ploutz-Snyder et al.,
1996), although other studies have failed to reproduce similar
results (Perry et al., 2007; Layec et al., 2012). It can therefore
be hypothesized that an EPO-induced increase in oxygen supply
could mediate a shift towards a more oxidative muscle, espe-
cially at supraphysiological EPO concentrations. Furthermore,
this adaptive process may be completely independent of the
EPO-R.
These inconsistent and inconclusive results obtain from
in vitro and in vivo rodent studies question the role of EPO in
muscle cell differentiation and survival and highlight the need
for more standardized studies. Ideally, mouse models display-
ing skeletal muscle specific EPO-R knockout or over expression
would be an important tool to assess the direct importance and
role of EPO and EPO-R in skeletal muscle. The use of a Cre/loxP
system to specifically knockout a target of interest in mouse skele-
tal muscle in vivo has been developed (McCarthy et al., 2012).
This inducible model is able to overcome limitations of tradi-
tional gene targeting strategies and can down regulate the target
of interest in a temporal and tissue-specific manner in the adult
animal following tamoxifen administration. For over expression
studies in adult animals, the use of adeno-associated viruses
(AAV) has now become a popular method to deliver stable gene
targets of interest into skeletal via intramuscular injection (Joanne
et al., 2013) or systemically via intravenous (Katwal et al., 2013)
or intraperitoneal administration (Charan et al., 2012).
IN HUMANS
In human skeletal muscle in vivo, a single EPO injection signif-
icantly increased the mRNA content of the myogenic regulatory
factor MRF-4 within 10 h (Lundby et al., 2008b). As resistance
exercise also increases MRF-4 transcription, it was suggested that
EPO might play a role in muscle fiber growth (Psilander et al.,
2003). Sixty-fiveminutes of cycling exercise resulted in an increase
in EPO-R mRNA levels in muscle biopsies collected 2 h post-
exercise when compared to pre-exercise levels (Rundqvist et al.,
2009). Recently it was shown that an acute systemic EPO injec-
tion did not increase the phosphorylation of members of STAT5,
MAPK, Akt and NFKB pathways in skeletal muscle (Figure 2)
when measured between 1 and 6 h following the EPO injection
(Christensen et al., 2012a). In addition, EPO-R phosphorylation
remained unchanged following EPO administration, although
the use of a phospho-EPO-R antibody in muscle extracts has
very little precedent in the literature. EPO administration also
increased resting energy expenditure but not insulin sensitivity.
While the mechanism controlling the EPO-induced increase in
energy expenditure was not established, there were no changes
in skeletal muscle mRNA expression of UCP-2, UCP-3, CPT-1 or
PPAR-α or in AMPK or ACC phosphorylation (Christensen et al.,
2012b). Fourteen weeks of EPO treatment had no effect on either
muscle fiber hypertrophy or angiogenesis (Lundby et al., 2008b).
Interestingly, it has been reported that patients with chronic renal
failure treated with EPO showed an increase in muscle fiber
diameter, especially in type I fibers, as well as an increase in glyco-
gen content when compared to non-treated patients (Davenport
et al., 1993). Long term EPO treatment had no effect on the
muscle membrane transport system, on the enzymes involved in
pH regulation or on the majority of proteins involved in acid–
base balance. It had no effect either on cytochrome C or on the
glycolysis enzyme hexokinase (Juel et al., 2007), a result in accor-
dance with those of Martinez-Bello (Martinez-Bello et al., 2012)
in the mouse soleus but not gastrocnemius muscle. However,
in line with previous results in rodents (Cayla et al., 2008;
Hojman et al., 2009), 8 weeks of EPO treatment enhanced skele-
tal musclemitochondrial oxidative phosphorylation andmaximal
electron transport capacity (Plenge et al., 2012). Interestingly,
prolonged EPO administration increased muscle capillary den-
sity in Friedreich Ataxia patients and may therefore contribute
to the improved motor function reported following EPO treat-
ment (Nachbauer et al., 2012). Altogether, these findings suggest
that in skeletal muscle in vivo, EPO may not activate the EPO-R
or the established EPO signaling cascades, such as JAK2/STAT5
or PI3-K/Akt. Additionally, the heterodimer receptor combining
the EPO-R and the βcR subunit, which was proposed to par-
tially or completely mediate the non-hematopoietic functions of
EPO, could not be detected in skeletal muscle at the gene or pro-
tein level (Rundqvist et al., 2009). Therefore, the effects of EPO
administration on human skeletal muscle growth and repair or
metabolism may not be exerted by a direct EPO/EPO-R interac-
tion, but rather be the consequence of a better oxygen supply to
the tissues.
CONCLUSION
The potential roles of EPO and its receptor in skeletal muscle have
raised frequent speculation, partially due to its widespread use in
endurance sport. Indeed, it has been suggested that EPO could
have a positive effect on skeletal muscle regeneration, growth,
oxidative capacity and angiogenesis. However, the role of EPO
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in skeletal muscle remains unclear and it is yet to be determined
whether its effects on the skeletal muscle lineage are compara-
ble to what is seen with the hematopoietic lineage. This review
provides a comprehensive picture of the work completed in this
area and highlights the strong need for more stringent, rigorous
and consistent studies in the future. We suggest that researchers
consider the different in vitro responses of immortalized cell
lines such as mouse C2C12 and rat L6 muscle cells when com-
pared with primary muscle cell lines, as well as species differences
between human and rodent primary muscle cell lines. The use
of overexpression or knockdown strategies that target the EPO-R
specifically in the adult skeletal muscle will significantly advance
our understanding of the role that EPO and the EPO-R play in
skeletal muscle biology. Finally, researchers should be aware of
the numerous commercially available EPO-R antibodies that are
non-specific and be able to demonstrate unequivocally the speci-
ficity of their chosen EPO-R antibody to detect the specific EPO-R
protein.
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